Physician profile
Gerard J Cusa
NPI 1619017910
$705.98
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $415 · 2020: $78.70 · 2021: $118 · 2022: $94.85.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $194.01 | 2019-2021 | |
| Boston Scientific Corporation | $126.48 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $90.03 | 2019-2022 | |
| Redhill Biopharma INC. | $86.30 | 2020-2022 | |
| Abbvie INC. | $48.63 | 2021 | |
| Pfizer INC. | $34.72 | 2022 | |
| Merck Sharp & Dohme LLC | $30.80 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.08 | 2019-2022 | |
| Qiagen, LLC | $20.14 | 2019 | |
| Daiichi Sankyo INC. | $17.23 | 2020 | |
| Ferring Pharmaceuticals INC. | $13.90 | 2019 | |
| Amarin Pharma, INC. | $13.66 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerard Cusa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.